US Broker Ratings

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenges in the Biotech Sector

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) stands at the intersection of biotechnology and innovation, offering a robust platform for cell engineering. Despite its promising technological capabilities, investors face a complex..

Arvinas, Inc. (ARVN) Stock Analysis: Uncovering a Potential 67.61% Upside in the Biotech Sector

Arvinas, Inc. (NASDAQ: ARVN), a prominent player in the biotechnology industry, is drawing attention from investors due to its innovative approach to drug development and a compelling potential upside of..

Dianthus Therapeutics (DNTH) Stock Analysis: Exploring a 39% Potential Upside in the Biotech Sector

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) has captured the spotlight in the biotechnology industry with its impressive growth trajectory and a compelling potential upside of 39.24%. As a clinical-stage biotech firm,..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Exploring a Potential 151.94% Upside in the Biotech Sector

For investors with a keen interest in the burgeoning field of gene therapy, Taysha Gene Therapies, Inc. (NASDAQ: TSHA) offers a compelling opportunity. With a market capitalization of $1.68 billion..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: A 166.83% Potential Upside in the Biotech Arena

Individual investors seeking to capitalize on the growth potential within the biotechnology sector may find Maze Therapeutics, Inc. (NASDAQ: MAZE) an intriguing opportunity. With a market capitalization of $1.3 billion,..

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: A Biotech Gem with 111% Potential Upside

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) has emerged as a compelling player in the healthcare sector, particularly within the biotechnology industry. The company, based in Boston, Massachusetts, is on a promising..

Precigen, Inc. (PGEN) Stock Analysis: A 84% Upside Potential Sparks Investor Interest

Investors looking for promising opportunities in the biotechnology sector may want to turn their attention to Precigen, Inc. (NASDAQ: PGEN), a company at the forefront of gene and cell therapy..

Bicycle Therapeutics (BCYC) Stock Analysis: Exploring a 158% Potential Upside in the Biotech Sector

Bicycle Therapeutics plc (NASDAQ: BCYC) stands out in the biotechnology sector with its innovative approach to addressing diseases underserved by current treatments. Based in Cambridge, United Kingdom, the company is..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating the Challenges in Diagnostics & Research

Myriad Genetics, Inc. (MYGN), a prominent player in the healthcare sector, particularly in diagnostics and research, is navigating a challenging financial landscape. With a market capitalization of approximately $395.99 million,..

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Exploring a 337% Potential Upside

Investors with an eye on the healthcare sector might find Akebia Therapeutics, Inc. (NASDAQ: AKBA) an intriguing prospect. Operating in the niche of drug manufacturing, particularly focusing on specialty and..

Verastem, Inc. (VSTM) Stock Analysis: Unveiling a 94% Potential Upside in the Biotech Arena

Verastem, Inc. (NASDAQ: VSTM), a burgeoning name in the biotechnology sector, is capturing the attention of investors with its promising potential upside of 94.26%. Specializing in the development and commercialization..

Inventiva S.A. (IVA): Analyst Ratings Signal a 297% Upside Potential for Biotech Innovator

Inventiva S.A. – American Depositary Shares (IVA) represents a compelling opportunity for investors seeking exposure to a high-risk, high-reward segment of the biotech industry. Specializing in developing novel oral small..

Embecta Corp. (EMBC) Investor Outlook: Navigating Challenges with a Strategic Focus on Diabetes Solutions

Embecta Corp. (NASDAQ: EMBC), a noteworthy player in the healthcare sector, is navigating the medical instruments and supplies industry with a specialized focus on diabetes care. As a company with..

Keros Therapeutics, Inc. (KROS) Stock Analysis: A Biotech Gem with 74.59% Upside Potential

Keros Therapeutics, Inc. (NASDAQ: KROS), a pioneering name in the biotechnology sector, presents a compelling investment opportunity with a potential upside of 74.59%. As a clinical-stage biopharmaceutical company, Keros is..

Personalis, Inc. (PSNL) Stock Analysis: A Bold Bet in Cancer Genomics with a 30% Revenue Surge

Personalis, Inc. (NASDAQ: PSNL), a prominent player in the healthcare sector specializing in diagnostics and research, is making waves with its innovative cancer genomic solutions. Headquartered in Fremont, California, the..

AnaptysBio, Inc. (ANAB) Stock Analysis: Exploring a Potential 62.78% Upside

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company based in San Diego, California, is making waves in the healthcare sector with a promising outlook for investors. Specializing in the development..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Unveiling a 24.41% Upside Potential in the Healthcare Sector

Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialized player in the healthcare sector, is capturing investor attention with its promising portfolio focused on rare disease treatments. Based in Deer Park, Illinois,..

Septerna, Inc. (SEPN) Investor Outlook: Strong Buy Ratings Signal 37% Potential Upside

Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company headquartered in South San Francisco, is making waves in the healthcare sector, specifically in biotechnology. With a market capitalization of $1.84 billion,..

Autolus Therapeutics plc (AUTL) Stock Analysis: A Biotech Pioneer with a Staggering 354% Potential Upside

Autolus Therapeutics plc (NASDAQ: AUTL), a prominent player in the biotechnology sector, is capturing investor attention with its significant potential upside of 354.43%, as per the latest analyst ratings. Headquartered..

Tilray Brands, Inc. (TLRY) Stock Analysis: Exploring a 92.73% Potential Upside for Investors

Tilray Brands, Inc. (NASDAQ: TLRY), a prominent player in the healthcare sector under the drug manufacturers – specialty & generic industry, presents an intriguing opportunity for investors, with a potential..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds